The agreement also provides Mylan with a right of first refusal for additional oral contraceptive products and certain additional markets, including Australia and Japan, where Mylan has a significant presence.
Robert Coury, vice chairman and CEO of Mylan, said: “Through our partnership with Famy Care, we have met another longstanding commitment by expanding our portfolio to create a women’s health care franchise for Mylan.
“We anticipate filing abbreviated new drug applications as early as the next few months and beginning to commercialize them in 2010.”